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Systematic review of antibiotic resistance in acne: 
an increasing topical and oral threat
Timothy R Walsh, John Efthimiou, Brigitte Dréno
Topical and oral antibiotics are routinely used to treat acne. However, antibiotic resistance is increasing, with many 
countries reporting that more than 50% of Propionibacterium acnes strains are resistant to topical macrolides, making 
them less eﬀ ective. We reviewed the current scientiﬁ c literature to enable proposal of recommendations for antibiotic 
use in acne treatment. References were identiﬁ ed through PubMed searches for articles published from January, 1954, 
to March 7, 2015, using four multiword searches. Ideally, benzoyl peroxide in combination with a topical retinoid 
should be used instead of a topical antibiotic to minimise the impact of resistance. Oral antibiotics still have a role in 
the treatment of moderate-to-severe acne, but only with a topical retinoid, benzoyl peroxide, or their combination, and 
ideally for no longer than 3 months. To limit resistance, it is recommended that benzoyl peroxide should always be 
added when long-term oral antibiotic use is deemed necessary. The beneﬁ t-to-risk ratio of long-term antibiotic use 
should be carefully considered and, in particular, use alone avoided where possible. There is a need to treat acne with 
eﬀ ective alternatives to antibiotics to reduce the likelihood of resistance.
Introduction
Topical and oral antibiotics are routinely used to treat 
acne. However, antibiotic resistance is increasing, with 
many countries reporting that over 50% of 
Propioni bacterium acnes strains are resistant to topical 
macro lides, making them less eﬀ ective. Collateral 
damage to the steady-state micro biome is a major 
concern, particularly for Staphylococcus aureus and 
meticillin-resistant S aureus (MRSA), and antibiotic 
resistance in non-target bacteria promotes the growth of 
opportunistic pathogens. The Global Alliance to Improve 
Outcomes in Acne recom mends that topical and oral 
antibiotics are not used as monotherapy or concurrently, 
and that combination of a topical retinoid and 
antimicrobial agent (eg, benzoyl peroxide [BPO]) is 
preferred as ﬁ rst-line therapy for almost all people with 
acne. To limit antibiotic resistance, BPO should always 
be added when long-term antibiotic use is deemed 
necessary. Com prehensive and detailed antibiotic 
resistance studies and joint recommendations from 
both dermatologists and microbiologists are long 
overdue. Here, we discuss the scientiﬁ c literature and 
propose recommendations for international imple-
mentation and further clinical microbiological studies. 
Search strategy and selection criteria
References were identiﬁ ed through searches of PubMed 
for articles published from January, 1954, to March 7, 
2015, using several search terms. 465 publications were 
identiﬁ ed using the search terms acne (all ﬁ elds) AND 
resistance (all ﬁ elds) NOT insulin, 323 of which were 
published after 2000. A search using the terms acne 
(all ﬁ elds) AND resistance (all ﬁ elds) AND macrolide (all 
ﬁ elds) led to the identiﬁ cation of 83 publications, 45 of 
which were published after 2000. 77 publications were 
identiﬁ ed using terms acne (all ﬁ elds) AND resistance 
(title) NOT insulin, 44 of which were published after 
2000. 24 of 77 publications were review articles, but four 
were excluded because they were not relevant to this 
Review. One 2010 review1 included a search via 
MEDLINE, and three older systematic reviews2–4 have 
been published. Other searches done were acne (title) 
AND antibiotic (title), which identiﬁ ed 107 publications, 
63 of which were published after 2000, and acne (title) 
AND therapy (title) NOT insulin, which identiﬁ ed 
749 publications, 287 of which were published after 2000. 
Articles resulting from these searches and relevant 
references cited in those articles were reviewed. Only 
articles published in English were included.
The number of publications found is relatively low as 
compared with other therapy areas. For example, a search 
using terms pneumonia (all ﬁ elds) AND resistance (all 
ﬁ elds) provides 7622 publications, 1694 of which are 
reviews. The development of antibiotic resistance as a 
result of antibiotic use in people with acne is a relatively 
unexplored area where further research is needed. This 
large, comprehensive systematic review has been done to 
highlight the importance and concern in this area, to 
discuss the scientiﬁ c literature currently available, and 
to propose recommendations to be internationally 
implemented. Such a systematic and comprehensive 
analysis has previously not been undertaken. 
Causes and pathogenesis of acne
Acne is a chronic inﬂ ammatory disorder of the skin 
associated with comedones, papules, pustules, nodules, 
and erythema, which can lead to scarring. It is very 
common, aﬀ ecting almost 80% of adolescents and young 
adults aged 11–30 years.5–7
The pathogenesis is complex, but the pilosebaceous unit 
is the target organ, which accounts for the distribution of 
acne primarily on the face, chest, and back—the areas 
with the highest concentration of pilosebaceous glands.6,8–10 
The most notable pathophysiological factors that aﬀ ect the 
development of acne are sebaceous gland hyperplasia 
with seborrhoea, altered follicular growth and dif-
ferentiation, P acnes colonisation of the follicle, and 
inﬂ am mation and immune response.8,11–15
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Of these factors, altered follicular growth and 
diﬀ erentiation and sebaceous hyperplasia are thought to 
be the most important because, together, they induce the 
microcomedo, the primary lesion of acne. The 
microcomedo can develop into either a non-inﬂ ammatory 
comedo or become inﬂ amed and present as a papule, 
pustule, or nodule. P acnes is a skin commensal that is 
present in small numbers in most post-pubertal 
individuals, and is found in increased numbers in 
abnormal skin environments—ie, increased sebum and 
abnormally desquamated corneocytes in the sebaceous 
follicles of people, including those without acne.14,16 
Additionally, androgens are thought to contribute to the 
pathogenesis of acne by aﬀ ecting the growth of follicular 
corneocytes.
Acne is clearly not primarily an infectious disease and 
simply killing P acnes might improve acne, but will not 
necessarily result in disease resolution or cure.17 The 
importance of the antibacterial and anti-inﬂ ammatory 
eﬀ ects of antibiotics in acne is unclear,18,19 and their 
individual contribution to clinical eﬃ  cacy remains 
unknown. However, antibiotics are thought to work 
largely by inhibiting inﬂ ammation,10 although this has 
not been reported in vivo, but rather has been suggested 
by large amounts of in-vitro data showing that antibiotics 
have actions independent of bacterial killing. Inﬂ am-
matory events have been shown to precede hyper-
keratinisation, and P acnes is thought to contribute to 
inﬂ ammation via activation of toll-like receptors on the 
membranes of inﬂ ammatory cells.20 Additionally, 
oxidised lipids in sebum can stimulate production of 
inﬂ ammatory mediators, which further drives the 
inﬂ ammatory process.
Antibiotics used in the treatment of acne
Both topical and oral antibiotics are traditionally used in 
the treatment of acne.17,21,22 Erythromycin and clindamycin, 
two of the longest used and most commonly prescribed 
topical antibiotics, are still frequently prescribed because 
side-eﬀ ects are typically minor.21–24 Topical antibiotics are 
usually used in the treatment of mild-to-moderate acne.17 
However, despite their modest eﬃ  cacy, their use continues 
and antibiotic resistance associated with topical antibiotic 
use, particularly macrolides, is an increasing concern.23,25–27 
Cyclines are the most commonly used oral antibiotics and 
tend to be used for the treatment of moderate-to-severe 
acne (ﬁ gure 1).17,23 As a result of increasing levels of 
resistance, use of oral erythromycin and other macrolides 
should be restricted to cases where cyclines are cont-
raindicated or not well tolerated.21,23 Use of oral clindamycin 
is associated with potentially serious gastrointestinal 
complications, and the need for periodic liver and kidney 
function test monitoring during prolonged therapy.28–31 
Furthermore, European guidelines speciﬁ cally state that 
oral clindamycin is not generally recommended for the 
treatment of acne.32 Cyclines, macrolides, and clindamycin 
are all bacteriostatic antibiotics so their use only slows 
bacterial growth and bacteria retain the potential to become 
resistant.23,33 However, antimicrobial therapies that 
maximise bactericidal eﬀ ects (eg, BPO) are essential 
because they kill the bacteria and thus reduce the likelihood 
of bacteria developing antibiotic resistance.17,33
Historically, topical antibiotics have been largely used 
for their antimicrobial properties.17 Antibiotic use 
directed against P acnes has been a mainstay of acne 
treatment for over 50 years.34 P acnes seems to play an 
integral part in the development of acne lesions both 
early and late in the pathophysiological process.35 It 
contributes to the development of retentional lesions by 
increasing the proliferation of keratinocytes and the 
expression of proteins implicated in the diﬀ erentiation of 
keratinocytes. Additionally, P acnes strongly activates 
innate immunity via toll-like receptor 2 and protease-
activated receptors—expressed by kera tinocytes—which 
induces the production of pro inﬂ ammatory cytokines 
and matrix metalloproteinases.35–37 Although acne is not 
an infection, antibiotic use reduces the number of P acnes 
present on the skin and in the pilosebaceous follicles, 
and results in clinical beneﬁ ts.1,17,21
Oral antibiotics (particularly cyclines) also have 
substantial anti-inﬂ ammatory properties, which could 
have an important role in addition to their antimicrobial 
eﬀ ects in acne,18,23 as they do in other areas of medicine 
where infection and inﬂ ammation can chronically 
coexist.38–42 However, oral antibiotics have only been 
shown to inhibit inﬂ ammation independent of bacterial 
Figure 1: Example of patient with severe acne likely to be treated with an 
oral antibiotic
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killing in vitro, an eﬀ ect not reported in vivo.23,43 The 
relative contribution of their antibacterial and anti-
inﬂ ammatory properties in the treatment of acne 
remains to be completely elucidated.43 Although low-dose 
oral antibiotics are used in the treatment of acne, this 
type of treatment has not been studied in detail, so robust 
conclusions cannot be drawn, particularly with regard to 
the overall beneﬁ t-to-risk ratio and implications for 
antibiotic resistance.17
Antibiotic use and resistance: a global issue
Although there is an enormous antibiotic load in the 
dermatology community, quantitative information on 
the use of antibiotics to speciﬁ cally treat acne is very 
limited. In the USA, dermatologists represent 1% or less 
of the physician population, but prescribe almost 5% of 
all antibiotics.44 Roughly 8% of all antibiotics prescribed 
in the UK are thought to be for dermatological 
indications.45 Crucially, no longitudinal studies of topical 
or oral antibiotic use in acne exist. The fact that people 
with acne often take prolonged courses of a single 
antibiotic, typically 3–6 months, will result in exposure at 
varying concentrations and potentiate resistance.43,46 
Further research is needed to accurately determine 
antibiotic use in the treatment of acne and whether any 
diﬀ erences in country or patterns of use exist.
Although not speciﬁ c to acne, recent publications have 
highlighted the fact that use of antibiotics is still 
increasing globally. From 2000–10, use of 16 groups of 
antibiotics across 71 countries increased by 36%.47 The 
latest data from the European Centre for Disease 
Prevention and Control on systemic use of antibacterials 
in the community (ie, outside hospitals) provide further 
evidence to support this increase. Belgium, Malta, and 
the UK all reported a substantial increase in antibiotic 
use between 2007 and 2011, but no country provided any 
evidence for a signiﬁ cant decrease (ﬁ gure 2).48
Antibiotic resistance is a continuing issue worldwide.49 
Margaret Chan, WHO Director-General, said, “a 
post-antibiotic era means, in eﬀ ect, an end to modern 
medicine as we know it”.50 In her annual report, 
Sally Davies, England’s Chief Medical Oﬃ  cer, stated: 
“antimicrobial resistance is a ticking time bomb not only 
for the UK but also for the world”.51 The excessive use 
and misuse of antibiotics has played an important part in 
the development of antibiotic resistance.52 Worryingly, 
antibiotics are prescribed when they are not needed or 
are misused as much as 50% of the time.33 Drug-resistant 
strains of bacteria are thought to be annually responsible 
for 5000 deaths in the UK, 25 000 deaths in Europe, and 
23 000 deaths in the USA.52,53
Crucially, few new agents have been discovered since 
1987,54,55 which might, in part, be due to woefully inadequate 
levels of funding. For example, less than 1% of available 
public and charitable research funding in the UK was 
awarded for research on antibiotics between 2008 and 
2013.56 One of the three strategic aims in the UK’s 2013–18 
antimicrobial resistance strategy is to stimulate the 
development of new antibiotics, diagnostics, and 
therapies.57 Additionally, a new collaboration involving all 
seven UK research councils, the Department of Health 
and other government departments, the Wellcome Trust, 
and other relevant organisations, has been launched with 
the aim to boost research into microbial resistance.58
Figure 2: Consumption of antibacterials for systemic use in the community for European Economic Area 
countries 2007–11, expressed as deﬁ ned daily dose per 1000 inhabitants per day48
Reproduced from reference 48, by permission of the European Centre for Disease Prevention and Control. 
*Romania and Spain provided reimbursement data (ie, not including use without a prescription and other non-
reimbursed courses). †Romania (2007, 2008, 2010) and Slovakia (2010) did not report data for these years. 
‡Cyprus (2007–11), Greece (2007, 2008, 2010), Iceland (2010, 2011), Lithuania (2007–09, 2011), and Slovakia 
(2011) provided only total care data (ie, including the hospital sector).
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At the end of 2014, the US President’s Council of 
Advisors on Science and Technology reported a proposed 
initiative involving three strategies to address the 
increasing problem of antibiotic resistance: better control 
through stewardship of antibiotic use, improved 
surveillance of antibiotic-resistant pathogens, and the 
development of new, more eﬀ ective antibiotics.59 In the 
UK, the National Institute for Health and Care Excellence 
released draft guidelines on antimicrobial stewardship 
for consultation, which recommended monitoring and 
assessment of antimicrobial pre scriptions, prescription 
reason documentation, and patient discussions about 
why an antimicrobial might not be the best option.60 In 
their editorial,61 Carl Nathan and Otto Cars highlight that 
the health-care community has not kept pace with the 
ability of many pathogens to develop resistance to 
antibiotics, which is a major global concern. This 
commentary includes a call to action suggesting that 
doctors could act not only individually and medically, but 
also collectively, to persuade elected oﬃ  cials to respond 
to expert panel recommendations and national leaders’ 
directives with the legislation, regulation, enforcement, 
and cooperation needed to ensure appropriate use of 
antibiotics. Also very encouraging is The Lancet Series on 
antimicrobial access and resistance examining inter-
ventions known to work, which, in synergy with a more 
transparent prescribing culture, could help to prevent the 
apparent inexorable march of antimicrobial resistance.62
Antibiotic resistance in acne
In 1976, no evidence of topical or oral antibiotic-resistant 
P acnes existed in more than 1000 people with acne.63 
However, the overall incidence of P acnes resistance 
increased from 20% in 1978 to 62% in 1996.64–67 Increases 
in P acnes resistance have now been reported in all 
major regions of the world, although the data for 
diﬀ erent antibiotics used and for diﬀ erent regions and 
countries remains incomplete.38 Many countries have 
reported that over 50% of P acnes strains are resistant, 
particularly to topical macrolides (ﬁ gure 3).23,25–27,38,68–73 
When clinicians consider diﬀ erent treatment options, 
they should be aware that antibiotic resistance is as 
important in the use of topical antibiotics as oral 
antibiotics.25–27,68–73
A correlation exists between the emergence of 
resistant P acnes and antibiotic use.17,27,74 Importantly, 
countries with low resistance levels have restricted 
antibiotic use to treat acne, which emphasises the need 
to reduce their use at a global level.27,75 Data from 
Hong Kong provide evidence of a link between the 
develop ment of antibiotic-resistant P acnes and 
increased age, a longer duration of acne, and a longer 
duration of antibiotic treatment.70 In another study74 
done in Japan, resistance of P acnes to antibiotics 
increased with disease severity. Antibiotic treatment is 
not a pre requisite for the development of antibiotic 
resistance.27,70 Resistant P acnes can spread to the skin of 
untreated contacts, which strongly correlates with 
antibiotic prescribing patterns.27
Consequences of antibiotic use in treating acne
Resistance, cross-resistance, and topical antibiotic failure
The potential negative consequences of antibiotic use to 
treat acne are numerous (ﬁ gure 4).17,27,76–80 Resistance in 
P acnes mainly arises from chromosomal point 
mutations.34,74,81 Non-resistant P acnes are killed or growth 
is slowed, while resistant P acnes grow and proliferate.33,52 
P acnes does not usually acquire resistance from other 
bacteria or transfer resistant determinants to other 
bacteria.27,74,82,83 Resistant P acnes strains can emerge 
quickly—for example, topical clindamycin monotherapy 
results in an increase in resistant P acnes count to more 
than 1600% of baseline values by week 16.84 Resident ﬂ ora, 
such as P acnes, are naturally resilient, so resistant variants 
can remain long after antibiotic treatment has stopped.17 
Cross-resistance is also a growing global concern.69,70
Resistance of P acnes to antibiotics can manifest as a 
reduced response, no response, or a relapse.17 Because 
resistance does not directly translate into treatment 
failure, acne is not a classic bacterial infection—partly 
due to the fact that antibiotics exert anti-inﬂ ammatory 
properties in addition to their antibacterial actions, and 
that the importance of infection versus inﬂ ammation in 
each patient is not known and not generally understood.17,85 
Topical macrolides are now less eﬀ ective in the treatment 
of acne. A review86 of controlled trials provided convincing 
evidence showing that the eﬃ  cacy of topical erythromycin 
on the reduction in both inﬂ ammatory and non-
inﬂ ammatory lesions signiﬁ cantly decreased over time. 
The authors concluded that the reduction was probably 
related to the development of resistant P acnes. As a 
consequence of the reduced eﬃ  cacy of erythromycin in 
reducing lesions over time, the use of erythromycin to 
treat acne is decreasing.75,87
Figure 3: Topical and oral antibiotic-resistant Propionibacterium acnes isolated from acne patients in diff erent 
countries8–10,47–52
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Selection pressure on the steady-state microbiome
Although acne-causing bacteria do not always respond to 
antibiotics, their use exerts selection pressure on non-target 
bacteria, which could develop antibiotic resistance and 
continue to grow and ﬂ ourish.17,45,52 For over a decade, 
treatment of acne with topical erythromycin for 3 months 
has been known to be suﬃ  cient to select resistant 
pathogenic bacteria. Mills and colleagues76 found that 
erythromycin-resistant, coagulase-negative staphylococci 
were isolated from the facial skin of 87% of patients at 
baseline versus 98% by week 12. During a 12 week 
regression phase, when the antibiotic was removed, the 
number of erythromycin-resistant, coagulase-negative 
staphylococci only decreased slightly. Importantly, the 
average density of resistant bacteria signiﬁ cantly increased 
with erythromycin treatment versus placebo, with no 
change during regression. Over the 12 week treatment 
period, increases in resistant bacteria were also recorded 
on the untreated back and in the anterior nares. Almost all 
resistant isolates were highly resistant to erythromycin. 
The development and spread of such highly resistant 
bacteria could potentially have serious consequences.
Levy and colleagues77 showed that colonisation and 
resistance of Streptococcus pyogenes in the oropharynx is 
associated with antibiotic therapy in people with acne. 
Patients treated with topical antibiotics, oral antibiotics, 
or both, had more than three times the risk of S pyogenes 
colonisation compared with patients not given antibiotic 
therapy (p=0·003). Importantly, use of oral only or topical 
only antibiotics resulted in similar increases in 
colonisation. A total of 85% of S pyogenes cultures grown 
from individuals using antibiotics were resistant to at 
least one tetracycline antibiotic versus 20% from those 
not using antibiotics (p=0·01). Again, this could 
contribute to diﬃ  cult-to-control infections.
Emergence of resistant pathogenic bacteria has also 
been observed with clindamycin treatment. In people 
with acne, 18·8% of P acnes strains and 51·7% of 
S epidermidis strains were resistant to clindamycin. Over 
80% of individuals who had clindamycin-resistant 
P acnes also had clindamycin-resistant S epidermidis.74 
Although S epidermidis is a ubiquitous member of the 
skin microbiota, it can possess pathogenic features. 
S epidermidis is frequently isolated from patients with 
opportunistic infections, and is a causative agent of 
hospital-acquired infections.88
Resistance can emerge quickly. After only 4 weeks of 
topical erythromycin use, the aerobic ﬂ ora of the face is 
dominated by erythromycin-resistant, coagulase-negative 
staphylococci. By week 12, erythromycin-resistant 
S epidermidis is the dominant species of staphylococci.89
Collateral damage to the steady-state microbiome
The eﬀ ects of topical and oral antibiotics on the 
steady-state microbiome diﬀ er. Although the use of 
topical antibiotics tends to result in antibiotic resistance 
conﬁ ned to the skin of the treated site, treatment with 
oral antibiotics can lead to antibiotic resistance in 
commensal ﬂ ora at all body sites.17 The development of 
antibiotic resistance, as a result of the treatment of an 
individual’s acne, can therefore promote the proliferation 
of opportunistic pathogens elsewhere in the body, so 
substantial collateral damage to the steady-state 
microbiome is a major concern, particularly for S aureus 
and MRSA.52,76 In fact, erythromycin-resistant S aureus 
carriage rates in the anterior nares increase from 15% to 
40% after 12 weeks of erythromycin treatment.76
We should remind ourselves that staphylococci bacteria 
are a major cause of health-care-associated infections. 
MRSA causes illnesses ranging from skin and wound 
infections to pneumonia and bloodstream infections that 
can cause sepsis and death. According to the US Centers 
for Disease Control and Prevention, MRSA has a threat 
level of serious, and erythromycin-resistant group A 
streptococcus and clindamycin-resistant group B 
streptococcus have a threat level of concerning.52
Although clindamycin and doxycycline are commonly 
used to treat acne, they are also treatments for MRSA.45 
Furthermore, clindamycin shows good tissue pene-
tration, and can be used to treat several serious infec tions 
(eg, osteomyelitis and cellulitis).90–92 The development of 
resistance to either of these antibiotics, due to their use 
instead of alternative acne treatment options, could limit 
their eﬃ  cacy in future.45
Figure 4: Potential consequences of antibiotic use to treat acne4,10,76–80
Teenager with acne  Treatment with antibiotic  
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Treatment of acne with antibiotics has been shown to 
increase the risk of common infections. In a retrospective 
cohort study78 involving 84 977 individuals with acne 
treated with a topical antibiotic, oral antibiotic, or both, 
the odds ratio of developing an upper respiratory tract 
infection diagnosed by a general practitioner was 
2·15 times higher compared with patients not treated 
with antibiotics (p<0·001). These ﬁ ndings were 
supported by a subsequent cross-sectional study,93 in 
which 66·7% of patients on oral antibiotics for their acne 
self-reported an episode of pharyngitis in the previous 
30 days, compared with 36·2% of individuals not given 
any oral antibiotics.
The dermatology community and all physicians 
treating people with acne should recognise the important 
eﬀ ects of antibiotic resistance. Individuals receiving an 
antibiotic for their acne who develop a more serious 
illness77,78,93 are likely to be seen by non-dermatology 
colleagues. This might provide insight into why the use 
of antibiotics, in particular topical antibiotics, to treat 
acne has not dramatically declined in the past 10 years.
Opportunistic infections
Evidence exists showing that P acnes can induce chronic 
and recurrent infections (with periods of relapse), such 
as endocarditis, mediastinitis after cardiac surgery, 
prosthetic joint infections, and breast implant 
infections.80,94–96 Mutations conferring P acnes resistance 
to rifampicin—an anti-bioﬁ lm, active antibiotic used to 
treat such infections—have been reported in 2013 and 
2014.80,97 The spread of resistant P acnes to an untreated 
contact could lead to the development of a resistant 
infection in someone less able to cope with the disease 
(eg, an elderly, immunosuppressed patient having 
cardiac surgery or another major surgery).27,80
Alternatives to antibiotics in the treatment of acne
Antibiotics still form a major part of acne therapy, despite 
the low availability of evidence-based data and few clinical 
trials on topical antibiotic monotherapy.23,45,98 Importantly, 
microbiology is not consistently done across all studies.84,99 
Moreover, detailed microbiological investigation, includ-
ing bacterial counts, typing, and minimum inhibitory 
concentration levels and molecular analysis, have been 
rarely done together.84 Many dermatologists might not 
fully appreciate the role of their specialty in potentially 
fuelling the problem of antibiotic resistance.44 However, 
antibiotic stewardship is a multidisciplinary initiative and 
is there to ensure that patients receive the right antibiotic, 
given in the correct way, in every case. Eﬀ orts to enhance 
the responsible use of antibiotics have been shown to 
improve outcomes and save money.52
Data to support the apparently practical and sensible 
recommendation not to use topical and oral antibiotics 
concurrently are limited, although this approach is 
recommended by international guidelines.17,23,100 The Global 
Alliance to Improve Outcomes in Acne, which brings 
together experts in the treatment of acne from around the 
world, has suggested several diﬀ erent strategies to reduce 
antibiotic resistance in P acnes and other bacteria (panel). 
The Alliance has reached a consensus that combination of 
a topical retinoid and antimicrobial agent (eg, BPO, an 
eﬀ ective non-antibiotic antimicrobial agent) is preferred as 
ﬁ rst-line therapy for almost all people with acne (ﬁ gure 5).17 
BPO is recommended as an addition to the topical 
treatment regimen when long-term antibiotic use is 
necessary, because it is a highly eﬃ  cient bactericidal agent 
that will minimise the development of resistance at sites of 
application.101–103 Topical antibiotics act relatively slowly on 
P acnes and have a poor suppressive eﬀ ect compared with 
BPO; oral antibiotics are generally considered to be more 
eﬀ ective than topical antibiotics. BPO is the most potent 
bactericidal agent against P acnes with evidence suggesting 
its use with a topical antibiotic improves eﬃ  cacy and 
reduces the risk of antimicrobial resistance.10,17,21,104 BPO 
rapidly reduces the number of sensitive and resistant 
strains of P acnes at the application site.17,105 Treatment with 
adapalene and BPO reduced both antibiotic-sensitive and 
antibiotic-resistant P acnes counts after only 4 weeks. The 
number of erythromycin-resistant and clindamycin-
resistant P acnes was reduced by several orders of 
magnitude, while P acnes resistant to one or more 
tetracycline decreased to levels close to total eradication.99 
Findings from the past 10 years have shown that acne 
improvement can be maintained with topical retinoids or 
combination of topical retinoid and BPO following initial 
treatment with antibiotics.106–108
Restriction of the use of topical antibiotics
Topical antibiotics should not be used as monotherapy. 
Their use in treating mild-to-moderate acne must be 
combined with a topical retinoid, BPO, or a ﬁ xed-dose 
combination of topical retinoid and BPO to provide 
Panel: Strategies from the Global Alliance to Improve 
Outcomes in Acne to reduce antibiotic resistance in 
Propionibacterium acnes and other bacteria4
First-line therapy
• Combine topical retinoid with antimicrobial (oral or topical)
If addition of antibiotic is needed:
• Limit to short periods; discontinue when only slight or no 
further improvement
• Oral antibiotics should ideally be used for 3 months
• Coprescribe benzoyl peroxide-containing product or use as 
washout
• Do not use as monotherapy
• Avoid concurrent use of oral and topical antibiotics
• Do not switch antibiotics without adequate justiﬁ cation
Maintenance therapy
• Use topical retinoids, with benzoyl peroxide added if 
needed
• Avoid antibiotics 
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synergistic, faster clearance, and be limited in duration. 
To reduce antibiotic resistance, it is recommended that 
BPO or a topical retinoid should always be added when 
long-term topical antibiotic use is necessary (panel, 
ﬁ gure 5). Topical and oral antibiotics should never be 
used concurrently. Ideally, BPO should be used in 
combination with a topical retinoid instead of a topical 
antibiotic to stop their use in acne and minimise the 
eﬀ ects of resistance.17
The eﬃ  cacy of topical antibiotics continues to be 
much debated. As an example, clindamycin mono-
therapy—even without resistance—is on the low end of 
the acne eﬃ  cacy spectrum, with evidence showing an 
eﬀ ect similar to vehicle.109 Despite this evidence, 
clindamycin use is thought to continue unabated.75 
However, use of erythromycin, the topical antibiotic 
associated with the highest level of P acnes resistance, is 
now decreasing.26,75,87
Combination of a topical retinoid with an antibiotic 
does not have the same eﬀ ect as combining it with BPO. 
For example, although treatment with clindamycin 
phosphate and tretinoin, and clindamycin phosphate and 
BPO reduced total P acnes counts over a 16 week period, 
overall reductions in clindamycin-resistant and 
erythromycin-resistant P acnes counts were only observed 
in the clindamycin phosphate and BPO arm. In the same 
study, treatment with clindamycin phosphate and 
tretinoin resulted in an increase in erythromycin-resistant 
counts from baseline to week 16.110
Restriction of the use of oral antibiotics
Oral antibiotics still have a role in the treatment of 
moderate-to-severe acne. However, they must always be 
combined with a topical retinoid, BPO, or a ﬁ xed-dose 
combination of topical retinoid and BPO, which has the 
advantage of a larger spectrum of activity. To reduce 
antibiotic resistance, it is recommended that BPO 
should always be added when long-term oral antibiotic 
use is necessary (panel, ﬁ gure 5).17 Since BPO is 
bactericidal, it kills the bacteria and reduces the 
likelihood of resistance.17,33 Some restrictions on the use 
of oral antibiotics are in place, which aim to reduce the 
risk of antibiotic resistance. In some countries, 
minocycline has been reserved for hospital prescription 
use only.111 In some countries, 100 mg doxycycline is the 
maximum licensed daily dose and 300 mg lymecycline 
is the maximum licensed daily dose.112
Oral antibiotics should be used carefully to treat acne, 
ideally for no longer than 3 months, as evidenced by 
diﬀ erent clinical studies that show little advantage in 
using them for a longer duration.106,113,114 Although these 
studies did not have the same objectives, use the same 
antibiotics, or assess the same lesion type, they each 
provide information about the duration of oral antibiotic 
use. Despite guidelines recommending that oral 
antibiotics be used only for 3 months, the mean duration 
of oral antibiotic use is 129 days, 17·5% of courses are 
longer than 6 months, 7% of courses are at least 9 months 
in duration, and 57·8% of all qualifying oral antibiotic 
Figure 5: Global Alliance to Improve Outcomes in Acne treatment algorithm4
BPO=benzoyl peroxide. Reproduced from reference 17, by permission of Elsevier. *With small nodules (less than 0·5 cm). †Second course in case of relapse. 
‡Consider physical removal of comedones. §No consensus on this alternative recommendation; however, in some countries azelaic acid prescription is appropriate 
practice. ¶For pregnancy, options are limited.
Comedonal
Mild SevereModerate
Mixed and papular or
pustular
Mixed and papular or
pustular
Nodular* Nodular or conglobate
Topical retinoidFirst choice
Acne severity
Alternatives‡
Alternatives for females‡¶
Maintenance therapy
Topical retinoid 
+ topical antimicrobial
Oral antibiotic 
+ topical retinoid
+/– BPO
Oral antibiotic 
+ topical retinoid
+ BPO
Oral isotretinoin†
Alternative topical 
retinoid or azelaic acid§
or salicylic acid
Alternative topical 
retinoid antimicrobial
agent 
+ alternative topical 
retinoid or azelaic acid§ 
Alternative oral antibiotic
+ alternative topical 
retinoid 
+/– BPO
Oral isotretinoin or
alternative oral antibiotic 
+ alternative topical 
retinoid 
+/– BPO or azelaic acid§
High-dose oral antibiotic 
+ topical retinoid
+ BPO
See first choice
Topical retinoid Topical retinoid +/– BPO
See first choice Oral antiandrogen21
+ topical retinoid/
azelaic acid§
+/– topical antimicrobial
Oral antiandrogen21
+ topical retinoid
+/– oral antibiotic 
+/–  alternative 
antimicrobial
High-dose oral 
antiandrogen21
+ topical retinoid
+/–  alternative topical 
antimicrobial
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courses do not include a concomitant topical retinoid.17,46 
Current international recommendations include 
restriction of the duration of antibiotic use to 3 months, 
avoidance of the use of topical and oral antibiotics 
concurrently, and addition of BPO to regress emergence 
of resistant bacteria. The inclusion of a topical retinoid to 
improve outcomes and for maintenance therapy, adding 
BPO if needed, has previously been recommended.17 
However, the amount of scientiﬁ c evidence supporting 
the 3 month duration of antibiotic treatment and the 
avoidance of combined use of topical and systemic 
antibiotics remains very small.
What does the future hold?
Antibiotic resistance in P acnes and other non-target 
bacteria as a result of topical antibiotics use in the 
treatment of acne is a major and increasing 
concern.26,52,69,76 The challenge is to curtail topical 
macrolide use, either alone or in combination with oral 
antibiotics. In combination with a topical retinoid, BPO 
provides a suitable alternative and reduces the likelihood 
of the emergence of antibiotic resistance.17 Oral 
antibiotics still have a place in the treatment of more 
severe acne, as long as the rules are followed.17 The 
prevalence of antibiotic-resistant P acnes strains is much 
lower than that reported for topical antibiotics across 
many countries.25–27,69,70,72 Furthermore, no link between 
cycline use, bacterial resistant strains, and failure of 
acne treatment has been shown so far. Further 
investigation into the use of sub-antimicrobial dose 
cyclines is clearly needed, particularly as the risk of 
developing antibiotic resistance is expected to be 
lower.17,18
Crucially, the study of antibiotic-resistant P acnes is 
associated with a variety of diﬀ erent methodological 
issues.75 Furthermore, the relative abundance of P acnes 
is similar in people with acne and healthy individuals, 
with certain strains highly associated with acne and other 
strains enriched in healthy skin.115 The culture of a few 
isolates from a disease lesion or healthy skin, therefore, 
might not provide an accurate and unbiased 
measurement of the association between diﬀ erent 
strains and the disease or antibiotic resistance.75
Detailed microbiological antibiotic resistance studies 
in people with acne are urgently needed and, parti cularly, 
comprehensive studies involving both microbiologists 
and dermatologists. There is also a need to revisit other 
antibiotic classes, such as the β lactams. The minimum 
inhibitory concentration susceptibility of P acnes to a 
variety of antibiotics should be tested across the globe, 
using routine methods, preferably with the addition of 
sebaceous ﬂ uid. Moreover, partial or whole genome 
sequencing, as shown in other therapy areas, will allow 
improved characterisation of drug-resistant organisms, 
establish ment of eﬀ ective versus ineﬀ ective antibiotics, 
and rapid comparison of resistant organisms isolated in 
the same centre and even around the world.116
Antibiotic resistance through inappropriate antibiotic 
use can have a huge eﬀ ect on the individual. In fact, the 
emotional and social impact of acne is more substantial 
than for some diseases that are generally considered more 
serious.117 Suicidal ideation and mental health problems 
are common in adolescents with acne (twice as common 
in girls and three times as frequent in boys) and become 
more frequent with increasing acne severity.118 Findings 
from a 2014 study119 have also shown that acne can develop 
in young children, so the eﬀ ect of antibiotic resistance in 
these subgroups should be actively considered. There is 
now, more than ever, a need to treat acne with eﬀ ective 
alternatives to antibiotics to minimise the chance of 
developing resistance, which has already reached worrying 
levels.
Limitations of current evidence base
So far, very few controlled, detailed clinical and 
microbiological studies investigating the use of antibiotic 
regimens, or comparing the outcomes with use of 
antibiotics for diﬀ erent lengths of time (eg, 1 vs 2 vs 3 vs 
4 months) have been done in people with acne, and even 
fewer studies relating microbiology to clinical outcomes 
are available. Additionally, little evidence exists on the 
clinical and microbiological consequences of antibiotic 
resistance in P acnes and the dermatological and non-
dermatological microbiome and collateral damage. Few 
controlled trials investigating eﬃ  cacy, safety, and 
antibiotic resistance of oral or topical antibiotics have 
been done, and detailed microbiology data are limited. 
Finally, antibiotics are thought to work principally 
through their anti-inﬂ ammatory eﬀ ects; however, this 
remains to be clearly shown in clinical studies. A few 
studies have suggested that low-dose oral antibiotics are 
beneﬁ cial because of their anti-inﬂ ammatory eﬀ ects 
without selective pressure on resident bacteria, but no 
detailed clinical and microbiological investigations have 
been undertaken, and such studies are much needed, 
given the associated risks.
Summary of treatment recommendations
Topical antibiotics used to treat mild-to-moderate acne 
should be limited in duration or avoided. Ideally, BPO 
combined with a topical retinoid should be used instead 
of a topical antibiotic to stop their use in acne and 
minimise the impact of resistance. Topical antibiotics 
should not be used as monotherapy. Topical and oral 
antibiotics should never be used concurrently. Oral 
antibiotics still have a role in the treatment of 
moderate-to-severe acne, but only in combination with a 
topical retinoid, BPO, or a ﬁ xed-dose topical retinoid and 
BPO combination, and ideally for no longer than 
3 months. To limit antibiotic resistance, BPO should 
always be added when long-term oral antibiotic use is 
necessary (panel, ﬁ gure 5). Acne improvement can be 
maintained with topical retinoids or a topical retinoid 
and BPO combination.4
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